European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
Posted:
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection.
Medway NHS Foundation Trust, one of the largest and most innovative NHS trusts in the South-East of England, has taken a bold step forward in its virtual care journey by transitioning to a new digital platform – part of its…
Chancellor Rachel Reeves announced that the government is investing up to £10bn to bring the NHS “into the digital age” as part of the latest spending review.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us